12:00 AM
 | 
Jan 09, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Halofuginone regulatory update

FDA granted Orphan Drug designation for Halo's HT-100 to treat Duchenne muscular dystrophy (DMD). Halo plans to begin...

Read the full 66 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >